

Nanoparticles and Nanocarriers- Based Pharmaceutical Formulations

Edited by

Akhlesh K. Jain

*Institute of Pharmaceutical Sciences
Guru Ghasidas University, Koni
Bilaspur, CG- 495009
India*

&

Keerti Mishra

*Institute of Pharmaceutical Sciences
Guru Ghasidas University, Koni
Bilaspur, CG- 495009
India*

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



Targeting Potential of Nanocarriers for Efficient Treatment of *H. Pylori* Infection

Sunil K. Jain^{1,*}, Kuldeep Rajpoot¹, K. Kesavan¹, Awesh Yadav², Umesh Gupta³ and Prem N. Gupta⁴

¹ Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur (C.G.) 495 009, India

² Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Raebareli, India

³ Department of Pharmacy, Central University of Rajasthan, Ajmer, Rajasthan 305801, India

⁴ CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu-180001, India

Abstract: *Helicobacter pylori* (*H. pylori*), a prevalent human-specific pathogen, plays a key role in the development of peptic ulcer disease, gastric carcinoma, and gastric mucosa associated lymphoid tissue lymphoma. **Once** infected, those bacteria reside below the gastric mucosa adherent to the gastric epithelium, and entry of drugs to this target site is very difficult. The bacteria can also acquire resistance to commonly used antimicrobial drugs. Thus, an effective antimicrobial concentration cannot be achieved in the gastric mucous layer or on the epithelial cell surfaces where *H. pylori* exist and caused inefficient treatment. Such challenges have encouraged researchers into developing some therapies based on nanotechnology.

Keywords: Antibiotics, Gastro-retentive delivery system, *H. pylori*, Nanoparticles, pH responsive nanoparticles, Herbal approach, Liposomes, Lectins, Nanogels, Nanoparticulate vaccine, Mucoadhesion, Nanocarriers, Nanolipobeads, Polymeric nano-micelles, Receptor mediated targeting.

1. INTRODUCTION

The incidence of *Helicobacter pylori* (*H. pylori*) is found to be between 85 to 95% in developing countries such as India, Malaysia, *etc* and 30 to 50% in developed countries such as the USA, Australia, UK, *etc*. The epidemiology of *H. pylori* infection has been changed with improved sanitation and methods of eradication.

* **Corresponding author Sunil K. Jain:** Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur (C.G.) 495 009, India; Tel: +91 94254 52174; E-mail: suniljain25in@yahoo.com

Gastro-retentive Nanocarriers in Drug Delivery

Kuldeep Rajpoot^{1,*}, Sunil K. Jain¹ and Saroj Dangi Rajpoot²

¹ Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, C.G. 495009, India

² Mahatma Gandhi Homoeopathic Medical College, Rani Durgavati Vishwavidyalaya, Jabalpur, M.P. 482001, India

Abstract: The oral route is an extremely accepted route for the administration of several drug delivery systems. This route exhibits several merits for the controlled and sustained release of different formulation types to attain enhanced therapeutic responses. Gastro-retentive nanocarriers (NCs) (GRNCs) have advantages due to their aptitude for extended retaining potential in the stomach environment and thereby elevate gastric retention and augmenting bioavailability of the drug molecules. This chapter covers various merits and demerits of gastro-retentive NCs. Further, it also discusses some gastro-retentive strategies and their applications in the therapy of various illnesses, for instance, swelling NCs, porous NCs, floating/non-floating NCs, lipid NCs, Polymeric NCs, bioadhesive NCs, and magnetic NCs, etc.

Keywords: Controlled drug release, Bioavailability, Drug delivery, Eudragit L100, Floating systems, Gastric cancer, Gastro-retentive carriers, Gastric retention time, Gastric emptying time, Gastrointestinal, HPMC, Ion-exchange resin, Lipids nanocarriers, Mucoadhesive nanocarriers, Magnetic nanocarriers, Polymer, Polymeric nanocarriers, Stomach, Sustained drug release, Super porous systems.

1. INTRODUCTION

Oral administration of formulations exhibits several merits such as flexibility in preparation, low price, ease of delivery, easy transport, as well as elevated patient compliance. Despite this, it is associated with some demerits like low bioavailability of drugs owing to the heterogeneity of the gastrointestinal (GI) environment, the poor gastric retention time (GRT) of the product, enzymatic actions, pH conditions of the GI tract (GIT), and surface area [1]. Furthermore, traditional drug delivery systems (DDS) have not shown great potential to combat the challenges levied by the GIT, for instance, imperfect drug release, less

* Corresponding author Kuldeep Rajpoot: Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur (C.G.) 495 009, India; Tel: ?????????; E-mail: kuldeep_sagar06@rediffmail.com

Nanoemulsion: A Potential Carrier for Topical Drug Delivery

Kesavan Karthikeyan^{1,*}, Parasuraman Mohan¹, Sunil K Jain¹, Olivia Parra-Marín² and Selvasankar Murugesan³

¹ Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, Chhattisgarh, India

² Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad Universitaria, 04510, Ciudad de México, Mexico

³ Mother and Child Health Department, SIDRA Medicine, Doha, Qatar

Abstract: Nanoemulsions (NEs) are stable nanocarrier systems consisting mainly of oil and water, which are stabilized by surfactant with cosurfactant. Due to their typical size, nano-emulsions are transparent or translucent, and minute droplet size makes them stable against sedimentation or creaming. The nanoemulsion system may be in the form of oil-in-water (O/W) or water-in-oil (W/O). The recent literature revealed that NEs as a colloidal carrier system has been confirmed to be a valuable strategy to improve the bioavailability of topically applied drugs. NE has been proposed as a viable alternative to conventional topical dosage forms due to the ability to overcome the skin/ocular barriers faced after administration. Better permeation rate, improved therapeutic efficacy and reduction of dose, non-specific toxicity, and targeted drug delivery system can improve drug effectiveness when drugs are incorporated into NEs. In recent years, research studies have focused more on ion nanoemulsion systems using a mixture of surfactants to solve critical factors, such as solubility, stability, and drug delivery applications. This chapter outlines the recent development in nanoemulsion as a delivery system to study topical drug delivery.

Keywords: Nanocarrier, Nanoemulsion, Ocular, Skin, Topical drug delivery.

1. INTRODUCTION

Oil and water are immiscible liquids for blending two phases; the phases are miscible with the addition of the third component like an emulsifier [1]. Uniting the combination of these phases requires energy contribution to make up dissimilar contacts between water-oil systems that can restore similar phase

* Corresponding author Kesavan Karthikeyan: Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, Chhattisgarh, India; E-mails: kesavanmpharm@gmail.com; k7_76@rediffmail.com